Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.


INTRODUCTION Erectile dysfunction (ED) is reported in a high percentage of patients with central neurological disorders (CND). AIM   An up-to-date review on oral phosphodiesterase 5 inhibitors (PDE5): sildenafil, tadalafil, and vardenafil for individuals with CND and ED. MAIN OUTCOME MEASURES Various questionnaires on ED, such as the International Index… (More)
DOI: 10.1111/j.1743-6109.2011.02615.x


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics